These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 25965958)

  • 21. A convenient synthesis of N,N'-dibenzyl-2,4-diaminopyrimidine-2'-deoxyribonucleoside and 1-methyl-2'-deoxypseudoisocytidine.
    Wellington KW; Ooi HC; Benner SA
    Nucleosides Nucleotides Nucleic Acids; 2009 Apr; 28(4):275-91. PubMed ID: 20183581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. On-line coupling of anion exchange and ion-pair chromatography for measurement of intracellular triphosphate metabolites of reverse transcriptase inhibitors.
    Kuklenyik Z; Martin A; Pau CP; Holder A; Youngpairoj AS; Zheng Q; Cong ME; Garcia-Lerma JG; Heneine W; Pirkle JL; Barr JR
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Nov; 877(29):3659-66. PubMed ID: 19783232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine.
    Maserati R; De Silvestri A; Uglietti A; Colao G; Di Biagio A; Bruzzone B; Di Pietro M; Re MC; Tinelli C; Zazzi M;
    AIDS; 2010 Apr; 24(7):1013-8. PubMed ID: 20124969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stereoselective C-glycosidation of D-fucose derivatives directed by the protective groups.
    Cortezano-Arellano O; Meléndez-Becerra CA; Cortés F; Sartillo-Piscil F; Cordero-Vargas A
    Carbohydr Res; 2014 Jul; 393():51-9. PubMed ID: 24893263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study.
    Ribera E; Larrousse M; Curran A; Negredo E; Clotet B; Estrada V; Sanz J; Berenguer J; Rubio R; Pulido F; Ferrer P; Alvarez ML; Arterburn S; Martínez E
    HIV Med; 2013 Jul; 14(6):327-36. PubMed ID: 23298339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficient large-scale synthesis of 5'-O-dimethoxytrityl-N4-benzoyl-5-methyl-2'-deoxycytidine.
    Ross BS; Han M; Ravikumar VT
    Nucleosides Nucleotides Nucleic Acids; 2006; 25(7):765-70. PubMed ID: 16898414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The antiretroviral potency of emtricitabine is approximately 3-fold higher compared to lamivudine in dual human immunodeficiency virus type 1 infection/competition experiments in vitro.
    Drogan D; Rauch P; Hoffmann D; Walter H; Metzner KJ
    Antiviral Res; 2010 Jun; 86(3):312-5. PubMed ID: 20302887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus.
    Saag MS
    Clin Infect Dis; 2006 Jan; 42(1):126-31. PubMed ID: 16323102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stereoselective formation of a cyclobutane pyrimidine dimer by using N4-acetyl protection of the cytosine base.
    Nishiguchi K; Yamamoto J; Iwai S
    Nucleic Acids Symp Ser (Oxf); 2008; (52):437-8. PubMed ID: 18776441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B.
    Fung S; Kwan P; Fabri M; Horban A; Pelemis M; Hann HW; Gurel S; Caruntu FA; Flaherty JF; Massetto B; Dinh P; Corsa A; Subramanian GM; McHutchison JG; Husa P; Gane E
    Gastroenterology; 2014 Apr; 146(4):980-8. PubMed ID: 24368224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand.
    Avihingsanon A; Lewin SR; Kerr S; Chang JJ; Piyawat K; Napissanant N; Matthews GV; Dore GJ; Bowden S; Lange J; Ruxrungtham K
    Antivir Ther; 2010; 15(6):917-22. PubMed ID: 20834105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The M184V mutation: what it does, how to prevent it, and what to do with it when it's there.
    Gallant JE
    AIDS Read; 2006 Oct; 16(10):556-9. PubMed ID: 17096474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A short, efficient synthesis of 2'-deoxypseudoisocytidine based on Heck-chemistry.
    Mayer A; Leumann CJ
    Nucleosides Nucleotides Nucleic Acids; 2003 Oct; 22(10):1919-25. PubMed ID: 14609231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects.
    Smith DE; Chan DJ; Maruszak H; Jeganathan S
    Int J STD AIDS; 2011 Apr; 22(4):228-30. PubMed ID: 21515757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and fluorescent properties of bi- and tricyclic 4-N-carbamoyldeoxycytidine derivatives.
    Miyata K; Mineo R; Tamamushi R; Mizuta M; Ohkubo A; Taguchi H; Seio K; Santa T; Sekine M
    J Org Chem; 2007 Jan; 72(1):102-8. PubMed ID: 17194087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New stereoselective beta-C-glycosidation by uncatalyzed 1,4-addition of organolithium reagents to a glycal-derived vinyl oxirane.
    Di Bussolo V; Caselli M; Pineschi M; Crotti P
    Org Lett; 2003 Jun; 5(12):2173-6. PubMed ID: 12790557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, enantiopure synthesis, and biological evaluation of novel iso-D-2',3'-dideoxy-3'-fluorothianucleoside derivatives as a bioisostere of lamivudine.
    Kim KR; Park AY; Moon HR; Chun MW; Jeong LS
    Nucleosides Nucleotides Nucleic Acids; 2007; 26(8-9):911-5. PubMed ID: 18058507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The development of β-selective glycosylation reactions with benzyl substituted 2-deoxy-1,4-dithio-D-
    Wishka DG; Lopez OD; Rudchenko VF; Huang G; Bahde R; Kumar V; Denysenko SM; Zhang L; Zhang M; Teicher BA; Morris J
    Nucleosides Nucleotides Nucleic Acids; 2021; 40(1):68-95. PubMed ID: 33063584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone.
    Muñoz de Benito RM; Arribas López JR
    Expert Rev Anti Infect Ther; 2006 Aug; 4(4):523-35. PubMed ID: 17009933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lead optimization and structure-based design of potent and bioavailable deoxycytidine kinase inhibitors.
    Jessop TC; Tarver JE; Carlsen M; Xu A; Healy JP; Heim-Riether A; Fu Q; Taylor JA; Augeri DJ; Shen M; Stouch TR; Swanson RV; Tari LW; Hunter M; Hoffman I; Keyes PE; Yu XC; Miranda M; Liu Q; Swaffield JC; David Kimball S; Nouraldeen A; Wilson AG; Foushee AM; Jhaver K; Finch R; Anderson S; Oravecz T; Carson KG
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6784-7. PubMed ID: 19836232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.